Oxford BioDynamics Share Price

AIM:OBDUK£10.3mPharmaceuticals & Biotech

OBD Share Price Performance

OBD Community Fair Values

View all narratives

Recent OBD News & Updates

No updates

Oxford BioDynamics Plc Key Details

Last Reported Earnings

Mar 31, 2025

Next Reporting Earnings

n/a

Earnings per share (EPS): -0.0064
Gross Margin: 51.45%
Net Profit Margin: -1,405.47%
Debt/Equity Ratio: 0%

View full report ›

Oxford BioDynamics Plc Competitors

View more competitors

About OBD

Founded: 2007
Employees: 44
CEO
WebsiteView website: www.oxfordbiodynamics.com

Oxford BioDynamics Plc, together with its subsidiaries, operates as a biotechnology company that discovers and develops biomarkers for use in the pharmaceutical and biotechnology industry primarily in the United States and the United Kingdom. The company provides EpiSwitch, a proprietary technology platform that enables screening, evaluation, validation, and monitoring of 3D genomic biomarkers to diagnose patients. Its products include EpiSwitch Prostate Screening Test (PSE), a prostate cancer screening test; EpiSwitch CiRT (Checkpoint Inhibitor Response Test), a blood test for predicting therapeutic response to checkpoint inhibitor immunotherapy; EpiSwitch CST (Covid Severity Test), an advanced blood test for the prediction of COVID-19 severity in adults; and EpiSwitch Explorer Array Kit for high-resolution 3D genome profiling. The company was incorporated in 2007 and is headquartered in Oxford, the United Kingdom.

U.K. Market Performance

7 Days: 0.6%
3 Months: 8.4%
1 Year: 6.9%
Year to Date: 7.1%

The market has been flat over the last week. As for the longer term, the market has risen 6.9% in the past 12 months. Looking forward, earnings are forecast to grow by 15% annually. Market details ›

🇪🇺 🇬🇧 Momentum Is Returning to European and UK Markets

Richard Bowman

July 2025

The tide is turning for UK & European markets. Index ETFs won’t cut it since sector spreads are massive. Picking the right companies matters now more than ever.

Last Week